In August 2026, Resilient Pharmaceuticals — formerly Lykos Therapeutics, before that MAPS PBC — resubmitted its New Drug Application for MDMA-assisted therapy for PTSD. The notable part is what is missing: the FDA’s 2024 Complete Response Letter recommended a new Phase 3 trial, and Resilient did not run one. Instead it references third-party datasets including a small VA study with long-term follow-up, adds a Phase 1 safety study in 32 healthy volunteers focused on cardiac monitoring, and submits an audit of the original Phase 3 data. It refiles into a changed climate: FDA finalized its psychedelic clinical-investigation guidance in July 2026, and Executive Order 14401 (April 2026) told FDA, HHS, DEA, and VA to accelerate. A resubmission is typically reviewed faster than a new one. None of that is approval.
What actually happened
Resilient Pharmaceuticals resubmitted its MDMA-assisted therapy NDA to the FDA in August 2026, roughly two years after the drug was rejected. The filing went in quietly — it surfaced through reporting, not a company launch announcement.
The company has changed names twice. MAPS PBC became Lykos Therapeutics, and Lykos became Resilient Pharmaceuticals. The molecule and the core Phase 3 dataset did not change with the letterhead.
What is new is the filing. In August 2026 Resilient put the New Drug Application for MDMA-assisted therapy for post-traumatic stress disorder back in front of the FDA. MAPS, the nonprofit that funded the original research program, responded to reporting of the resubmission on August 10, 2026: https://maps.org/2026/08/10/maps-responds-to-report-of-progress-for-mdma-assisted-therapy-for-ptsd-with-fda/
Psychedelic Alpha’s account is the most detailed public reporting on what is inside the package: https://psychedelicalpha.com/news/two-years-after-rejection-resilient-quietly-refiles-mdma-for-ptsd-application/
The word “quietly” in that headline is doing real work. This is not how a company behaves when it is confident of a parade.
What the FDA asked for in 2024
The Complete Response Letter cited durability of response, safety characterization, and steps to minimize bias — and recommended a new Phase 3 trial. Functional unblinding was the structural problem underneath all three.
The FDA issued the Complete Response Letter in August 2024, after an advisory committee voted against the application. Three issues drove it: incomplete collection of adverse events, insufficient durability data, and bias concerns — including high rates of prior MDMA use among participants and prescreening failures.
The agency’s recommendation was a new trial designed to demonstrate durability, minimize bias, and characterize safety better.
The hard problem beneath all of it is functional unblinding. In a trial of a drug that produces an unmistakable subjective effect, participants and therapists usually know which arm they are in. That is not a paperwork issue; it is a threat to every efficacy number the study produces. The FDA has kept scrutinizing it across the whole psychedelic field, not just this application. It is the reason a “positive” psychedelic trial does not settle an argument the way a positive cardiology trial does.
Resilient did not run the new trial
Instead of a fresh Phase 3, the resubmission references third-party datasets — including a small VA study with long-term follow-up — plus a new Phase 1 cardiac-safety study in 32 healthy volunteers and an audit of the original Phase 3 data.
This is the decision the whole story turns on.
A new Phase 3 in PTSD is a multi-year, nine-figure undertaking for a company that laid off most of its staff after the 2024 rejection. Resilient’s answer is to assemble a package out of what already exists:
Third-party data. Rather than generate its own new efficacy trial, Resilient references other groups’ studies of the same compound, including a small VA study with a long-term follow-up component and at least one additional third-party dataset. Referencing outside data is a legitimate regulatory strategy. It is also weaker than owning the trial, because you did not control the protocol.
A new Phase 1. A safety study in 32 healthy volunteers, focused on cardiac monitoring — EKG and corrected QT interval. That responds directly to the safety-characterization criticism.
An audit. A formal review of the original Phase 3 data, which speaks to the data-integrity questions that dogged the program through 2024.
What is *not* in there is a new adequately powered efficacy trial with a bias-minimizing design. The FDA recommended one. Resilient is arguing it does not need one. The agency gets to decide whether that argument holds — and a Complete Response Letter recommendation is not a binding requirement, which is precisely the gap Resilient is walking through.
The climate changed more than the data did
FDA finalized its psychedelic clinical-investigation guidance in July 2026, and Executive Order 14401 (April 2026) directed FDA, HHS, DEA, and VA to accelerate psychedelic research and review. The application is refiling into a different political weather system.
Two things moved between the rejection and the refiling, and neither is a new efficacy result.
Final FDA guidance. In July 2026 the agency finalized *Psychedelic Drugs: Considerations for Clinical Investigations*, converting the 2023 draft into a settled document. We covered that, and the VA’s PIVOT psilocybin trial, in /blog/legal-updates/psychedelic-policy-briefing-august-2026. Guidance is non-binding, but it tells sponsors what the reviewers are thinking.
Executive Order 14401. Signed April 2026, directing FDA, HHS, DEA, and VA to accelerate psychedelic research and regulatory review. An executive order does not approve a drug or change an evidentiary standard. It does change how much institutional friction a sponsor expects.
Be careful with the causal story here. A more receptive climate is a reason a company files. It is not evidence that the medicine works. The 2024 concerns — durability, adverse-event capture, unblinding — are empirical questions, and a supportive executive order does not answer any of them.
One procedural note that matters for timing: reviews of resubmissions are generally faster than reviews of original applications. So the answer may arrive sooner than the two-year gap would suggest.
Two other things worth logging this week
Canada committed C$24 million to a national cannabis and brain health consortium, and Definium’s oral LSD tablet met its Phase 3 primary endpoint in generalized anxiety disorder.
Canada, August 12, 2026. The Canadian Institutes of Health Research announced C$24 million to establish the country’s first national cannabis and brain health research consortium across universities and medical centers. Not psilocybin, but the same broader current: public money moving into controlled-substance neuroscience.
Definium Therapeutics, August 12, 2026. DT120-ODT, an oral LSD tablet, met the primary endpoint in the Phase 3 Voyage study — a statistically significant reduction in Hamilton Anxiety Rating Scale scores at 12 weeks versus placebo — along with key secondary endpoints. The stock moved double digits. A potential NDA filing is discussed for the first half of 2027, with a further read-out (Panorama) due September 2026.
The design detail worth noticing: this is a single supervised dose not paired with extensive psychotherapy. That is a different product model from MDMA-assisted therapy, where the psychotherapy is inseparable from the intervention — and it is exactly the model that sidesteps the “are you approving a drug or a therapy?” problem that helped sink the 2024 MDMA application. If a lightly-supervised psychedelic clears FDA before a therapy-paired one does, that will shape what the industry builds next.
Background on anxiety indications: /conditions/anxiety.
PsyBear takeaways
A refiling is a filing, not an approval. The evidentiary questions from 2024 have not been answered with new efficacy data — they have been answered with a different argument. Veterans should still go through trials, not the underground.
1. Resubmission ≠ approval. The FDA has to accept the filing, review it, and decide. Anyone telling you MDMA therapy is approved, or imminent, is ahead of the facts.
2. The missing Phase 3 is the story. The agency recommended a new trial. The sponsor did not run one and is arguing from third-party data, a Phase 1 cardiac study, and an audit. That is a real strategy and a real gamble, and it deserves to be reported as both.
3. Functional unblinding is still unsolved. Nothing in this package fixes the fact that people know when they have taken MDMA. Until the field has a credible answer, every psychedelic efficacy estimate carries an asterisk.
4. A favorable executive order is not data. EO 14401 and the July guidance lower friction. They do not raise the evidence. Keep those two things in separate columns.
5. Veterans: trials, not shortcuts. PTSD is the indication driving the politics here, and the federal research pathway is real — see /for/veterans and /conditions/ptsd. A pending NDA is not a treatment you can access, and MDMA remains Schedule I outside authorized research.
6. Psilocybin is on a separate track. Do not read an MDMA filing as movement on mushrooms. The licensed psilocybin paths remain Oregon and Colorado: /legal-status/oregon, /legal-status/colorado, /legal-status.
MDMA is a Schedule I controlled substance under U.S. federal law outside authorized research. There is no approved MDMA-assisted therapy in the United States. This article is education and commentary on a regulatory filing, not medical advice, and not a suggestion to seek MDMA outside a clinical trial.
Key Takeaways
In August 2026, Resilient Pharmaceuticals — formerly Lykos Therapeutics, before that MAPS PBC — resubmitted its New Drug Application for MDMA-assisted therapy for PTSD. The notable part is what is missing: the FDA’s 2024 Complete Response Letter recommended a new Phase 3 trial, and Resilient did not run one. Instead it references third-party datasets including a small VA study with long-term follow-up, adds a Phase 1 safety study in 32 healthy volunteers focused on cardiac monitoring, and submits an audit of the original Phase 3 data. It refiles into a changed climate: FDA finalized its psychedelic clinical-investigation guidance in July 2026, and Executive Order 14401 (April 2026) told FDA, HHS, DEA, and VA to accelerate. A resubmission is typically reviewed faster than a new one. None of that is approval.
FAQ
- Has the FDA approved MDMA-assisted therapy for PTSD?
- No. Resilient Pharmaceuticals resubmitted its New Drug Application in August 2026, two years after the FDA issued a Complete Response Letter in August 2024. A resubmission means the FDA will review the application again. MDMA remains a Schedule I substance with no approved therapeutic use in the United States.
- Why did the FDA reject MDMA-assisted therapy in 2024?
- The Complete Response Letter cited incomplete adverse-event collection, insufficient durability data, and bias concerns including high rates of prior MDMA use among trial participants. The agency recommended a new Phase 3 trial designed to demonstrate durability, minimize bias, and better characterize safety.
- Did Resilient run the new Phase 3 trial the FDA recommended?
- No. The resubmission references third-party datasets instead, including a small VA study with long-term follow-up, plus a new Phase 1 safety study in 32 healthy volunteers focused on cardiac monitoring, and an audit of the original Phase 3 data. A CRL recommendation is not binding, but skipping it is a regulatory gamble.
- What is Resilient Pharmaceuticals?
- The company developing MDMA-assisted therapy for PTSD. It was previously named Lykos Therapeutics, and before that MAPS PBC — the public-benefit corporation spun out of the nonprofit Multidisciplinary Association for Psychedelic Studies, which funded the original research.
- When will the FDA decide on the MDMA application?
- No public decision date has been confirmed. Reviews of resubmissions are generally faster than reviews of original applications, so a decision may come sooner than the 2024–2026 gap suggests. Treat any specific date circulating without an FDA or company source as speculation.